Back to Search
Start Over
Pharmacotherapies for Migraine and Translating Evidence From Bench to Bedside.
- Source :
-
Mayo Clinic proceedings [Mayo Clin Proc] 2024 Feb; Vol. 99 (2), pp. 285-299. Date of Electronic Publication: 2024 Jan 05. - Publication Year :
- 2024
-
Abstract
- Migraine is a ubiquitous neurologic disorder that afflicts more than 1 billion people worldwide. Recommended therapeutic strategies include the use of acute and, if needed, preventive medications. During the past 2 decades, tremendous progress has been made in better understanding the molecular mechanisms underlying migraine pathogenesis, which in turn has resulted in the advent of novel medications targeting signaling molecule calcitonin gene-related peptide or its receptor. Here, we provide an update on the rational use of pharmacotherapies for migraine to facilitate more informed clinical decision-making. We then discuss the scientific discoveries that led to the advent of new medications targeting calcitonin gene-related peptide signaling. Last, we conclude with recent advances that are being made to identify novel drug targets for migraine.<br /> (Copyright © 2023 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 1942-5546
- Volume :
- 99
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Mayo Clinic proceedings
- Publication Type :
- Academic Journal
- Accession number :
- 38180396
- Full Text :
- https://doi.org/10.1016/j.mayocp.2023.07.003